Janine Kutzsche, Gustavo A Guzman, Antje Willuweit, Olaf Kletke, Esther Wollert, Ian Gering, Dagmar Jürgens, Jörg Breitkreutz, Holger Stark, Annette G Beck-Sickinge, Nikolaj Klöcker, Patricia Hidalgo, Dieter Willbold
BACKGROUND AND PURPOSE: Neuropathic pain (NP) affects up to 10 % of the global population and is caused by an injury or a disease affecting the somatosensory, peripheral, or central nervous system. NP is characterized by chronic, severe, and opioid-resistant properties. Therefore, its clinical management remains very challenging. The N-type voltage-gated calcium channel Cav 2.21 is a validated target for therapeutic intervention in chronic and neuropathic pain. The conotoxin Prialt is an FDA-approved drug that blocks Cav 2...
December 29, 2023: British Journal of Pharmacology